...
aplm-img

Apollomics Inc. Class A Ordinary Shares, Common Stock

APLM

NAQ

$8.255

+$0.37

(4.69%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$16.52M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
8.93K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.21
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.5 L
$105 H
$8.255

About Apollomics Inc. Class A Ordinary Shares, Common Stock

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameAPLMSectorS&P500
1-Week Return2.47%-3.39%-3.47%
1-Month Return-59.33%-3.25%-0.29%
3-Month Return-37.87%-11.61%4.5%
6-Month Return-61.7%-5.89%6.91%
1-Year Return-89.75%2.65%23.79%
3-Year Return-99.2%0.56%28.43%
5-Year Return-99.2%34.63%83.64%

Financials

Dec '20Dec '21Dec '22Dec '23
Total Revenue1.84M2.00K323.00K821.00K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.11,"profit":true},{"date":"2022-12-31","value":17.57,"profit":true},{"date":"2023-12-31","value":44.67,"profit":true}]
Cost of Revenue609.00K681.00K775.00K694.00K[{"date":"2020-12-31","value":78.58,"profit":true},{"date":"2021-12-31","value":87.87,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.55,"profit":true}]
Gross Profit1.23M(679.00K)(452.00K)127.00K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-55.25,"profit":false},{"date":"2022-12-31","value":-36.78,"profit":false},{"date":"2023-12-31","value":10.33,"profit":true}]
Gross Margin66.87%(33950.00%)(139.94%)15.47%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-50773.07,"profit":false},{"date":"2022-12-31","value":-209.28,"profit":false},{"date":"2023-12-31","value":23.13,"profit":true}]
Operating Expenses40.75M50.27M44.39M54.14M[{"date":"2020-12-31","value":75.28,"profit":true},{"date":"2021-12-31","value":92.86,"profit":true},{"date":"2022-12-31","value":81.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(74.08M)(91.75M)(240.21M)(54.83M)[{"date":"2020-12-31","value":-7408500000,"profit":false},{"date":"2021-12-31","value":-9175100000,"profit":false},{"date":"2022-12-31","value":-24021100000,"profit":false},{"date":"2023-12-31","value":-5483400000,"profit":false}]
Total Non-Operating Income/Expense(37.78M)(44.14M)(196.41M)(117.15M)[{"date":"2020-12-31","value":-3778300000,"profit":false},{"date":"2021-12-31","value":-4414200000,"profit":false},{"date":"2022-12-31","value":-19640700000,"profit":false},{"date":"2023-12-31","value":-11715400000,"profit":false}]
Pre-Tax Income(74.91M)(94.80M)(240.81M)(172.59M)[{"date":"2020-12-31","value":-7490500000,"profit":false},{"date":"2021-12-31","value":-9479600000,"profit":false},{"date":"2022-12-31","value":-24081000000,"profit":false},{"date":"2023-12-31","value":-17259100000,"profit":false}]
Income Taxes(85.00K)1.00K1.00K10.00K[{"date":"2020-12-31","value":-850,"profit":false},{"date":"2021-12-31","value":10,"profit":true},{"date":"2022-12-31","value":10,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(74.82M)(94.80M)(240.81M)(172.60M)[{"date":"2020-12-31","value":-7482000000,"profit":false},{"date":"2021-12-31","value":-9479700000,"profit":false},{"date":"2022-12-31","value":-24081100000,"profit":false},{"date":"2023-12-31","value":-17260100000,"profit":false}]
Income From Continuous Operations(74.82M)(94.80M)(240.81M)(172.60M)[{"date":"2020-12-31","value":-7482000000,"profit":false},{"date":"2021-12-31","value":-9479700000,"profit":false},{"date":"2022-12-31","value":-24081100000,"profit":false},{"date":"2023-12-31","value":-17260100000,"profit":false}]
Income From Discontinued Operations----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(74.82M)(94.80M)(240.81M)(172.60M)[{"date":"2020-12-31","value":-7482000000,"profit":false},{"date":"2021-12-31","value":-9479700000,"profit":false},{"date":"2022-12-31","value":-24081100000,"profit":false},{"date":"2023-12-31","value":-17260100000,"profit":false}]
EPS (Diluted)-(0.03)(0.05)-[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-3,"profit":false},{"date":"2022-12-31","value":-5.44,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

APLM
Cash Ratio 2.05
Current Ratio 2.25

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

APLM
ROA (LTM) -62.74%
ROE (LTM) -149.31%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

APLM
Debt Ratio Lower is generally better. Negative is bad. 0.40
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.60

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

APLM
Trailing PE NM
Forward PE NM
P/S (TTM) 4.14
P/B 0.42
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Apollomics Inc. Class A Ordinary Shares share price today?

Apollomics Inc. Class A Ordinary Shares (APLM) share price today is $8.255

Can Indians buy Apollomics Inc. Class A Ordinary Shares shares?

Yes, Indians can buy shares of Apollomics Inc. Class A Ordinary Shares (APLM) on Vested. To buy Apollomics Inc. Class A Ordinary Shares from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in APLM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Apollomics Inc. Class A Ordinary Shares be purchased?

Yes, you can purchase fractional shares of Apollomics Inc. Class A Ordinary Shares (APLM) via the Vested app. You can start investing in Apollomics Inc. Class A Ordinary Shares (APLM) with a minimum investment of $1.

How to invest in Apollomics Inc. Class A Ordinary Shares shares from India?

You can invest in shares of Apollomics Inc. Class A Ordinary Shares (APLM) via Vested in three simple steps:

  • Click on Sign Up or Invest in APLM stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Apollomics Inc. Class A Ordinary Shares shares
What is Apollomics Inc. Class A Ordinary Shares 52-week high and low stock price?

The 52-week high price of Apollomics Inc. Class A Ordinary Shares (APLM) is $105. The 52-week low price of Apollomics Inc. Class A Ordinary Shares (APLM) is $6.5.

What is Apollomics Inc. Class A Ordinary Shares price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Apollomics Inc. Class A Ordinary Shares (APLM) is

What is Apollomics Inc. Class A Ordinary Shares price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Apollomics Inc. Class A Ordinary Shares (APLM) is 0.42

What is Apollomics Inc. Class A Ordinary Shares dividend yield?

The dividend yield of Apollomics Inc. Class A Ordinary Shares (APLM) is 0.00%

What is the Market Cap of Apollomics Inc. Class A Ordinary Shares?

The market capitalization of Apollomics Inc. Class A Ordinary Shares (APLM) is $16.52M

What is Apollomics Inc. Class A Ordinary Shares’s stock symbol?

The stock symbol (or ticker) of Apollomics Inc. Class A Ordinary Shares is APLM

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top